In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

CANCELLED - Noninvasive recognition of experimental cardiac allograft rejection by molecular targeting of apoptotic process with radiolabeled duramycin in vivo

Session Patient management - From oral treatment to transplant


Congress : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Heart Transplantation
  • Session type : Rapid Fire Abstracts
  • FP Number : 1548

Authors : M Adapoe (New York,US), A Petrov (New York,US), F Chaudhry (New York,US), N Narula (New York,US), B Gray (West Chester,US), Y Pak (West Chester,US), HW Strauss (New York,US), P Heeger (New York,US), J Narula (New York,US)


M Adapoe1 , A Petrov1 , F Chaudhry1 , N Narula1 , B Gray2 , Y Pak2 , HW Strauss1 , P Heeger1 , J Narula1 , 1Icahn School of Medicine at Mount Sinai - New York - United States of America , 2Molecular Targeting Technologies Inc - West Chester - United States of America ,


Background: Myocardial apoptosis, a cellular death process distinctly different from the cellular necrosis has been described as an obligatory component of moderate and severe cardiac allograft rejection (CAR) in addition to interstitial inflammation. In clinical practice, CAR is universally detected by an invasive endomyocardial biopsy repeated at least 10-12 times in the first year after heart transplantation. Therefore, the importance of a noninvasive test can hardly be overstated.

Objective: Since apoptosis almost always accompanies CAR, and offers cell membrane signatures of the death process in form of asymmetric exposure of phosphatidylserine and phosphatidylethanolamine (PE), we evaluated the usefulness of radiolabeled PE-targeting agent- Technetium-99m-labeled duramycin (D) by microSPECT/CT imaging.

Methods: 16 mice received abdominal heterotopic cardiac allografts in 4 groups of 4 animals each. Group 1: BALB/c (H-2d) donor to B6 (H-2b) recipient (allogeneic transplant, ALO). Group 2: B6 donor to B6 recipient (syngeneic control transplant, CON). Group 3: BALB/c donor to B6 recipient treated with CTLA4-IG (allogeneic transplant and immunosuppressed, IMS). Group 4: Bm12 H-2bm12) donor to B6 recipient (class II MHC disparate transplant to test for chronic CAR, CHR). ALO and CON were sacrificed 6-7 days following transplant. IMS animals were sacrificed 14-15 days following transplant. CHR animals were sacrificed 21 days following transplant (all grafts were beating at the time of harvest). MicroSPECT/CT imaging of the heterotopic transplant was performed in vivo and ex vivo after intravenous D administration. The transplant was collected for quantitative injected dose/gram uptake (%ID/g) of radiotracer. Hearts were then pathologically characterized using the ISHLT grading rubric.

Results: The in vivo and ex vivo imaging, and the quantitative uptake (expressed in mean %ID/g ±SD) of the radiotracer demonstrated the most intense uptake in ALO (5.8±2.2 %ID/g), followed by CHR (1.8±1.5 %ID/g), then IMS (1.2±0.4 %ID/g), and finally CON (0.90±0.04 %ID/g). One-way ANOVA with Tukey post-hoc test revealed ALO had significantly higher uptake than that of the CON and IMS groups (P<0.05).  Pathology demonstrated ISHLT Grade 3R rejection in ALO (3 out of 4 animals), no rejection in CON and Grade 1-2R in IMS and CHR groups. Chronic vasculopathy was also observed in the CHR group.
Conclusion: Noninvasive molecular imaging of apoptosis in CAR is feasible with radiolabeled D, which can identify various shades of graft rejection verified by histopathological characterization.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are